ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0259

Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA

Ju Yeon Kim1, Kichul Shin2, Eun Bong Lee1 and Jun Won Park1, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: Biologicals, Comorbidity, Disease Activity, functional status, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: This study aims to evaluate the impact of comorbidities on disease activity and functional disability in patients with RA treated with biological disease-modifying anti-rheumatic drugs (bDMARDs).

Methods: We analyzed longitudinal data of 2,127 patients in a nationwide cohort of RA receiving bDMARD in South Korea (KOBIO-RA). Patients were enrolled at the time of starting bDMARD and followed up yearly thereafter. In this study, follow-up was censored when initial bDMARD was discontinued or at seventh visit, whichever came first. Functional status was assessed using Routine Assessment of Patient Index Data 3 (RAPID3). In each follow-up visit, we assessed whether the patient attained the minimal clinically important difference (MCID, defined as a 3.6-point decrease from baseline) in RAPID3 and low disease activity (LDA) based on Clinical Disease Activity Index (CDAI). Effect of comorbidities on these responses was analyzed using generalized estimating equations (GEE).

Results: At baseline, the mean (SD) disease activity was 15.25 (5.67) for RAPID3 and 26.85 (11.15) for CDAI. During the follow-up encompassing 5244 1-year intervals, 3489 (66.5%) and 3788 (74.0%) intervals achieved the MCID-RAPID3 and CDAI-LDA, respectively. Ischemic heart disease (adjusted OR 0.41 [0.22-0.76]), interstitial lung disease (adjusted OR 0.49 [0.33-0.72]), obstructive lung disease (adjusted OR 0.46 [0.25-0.85]), and depression (adjusted OR 0.56 [0.29-0.97]) were associated with poor RAPID3 response (Figure). Other comorbidities did not significantly influence the functional status. Presence of comorbidities was not associated with disease activity of RA except for pulmonary disease. Patients with interstitial lung disease or obstructive lung disease showed a significantly less likelihood of achieving CDAI-LDA (adjusted OR 0.58 [0.40-0.83] and 0.33 [0.19-0.57], respectively).

Conclusion: Pulmonary diseases were associated with higher patient reported functional index and disease activity in RA, while ischemic heart disease and depression were associated function index independent of the disease activity.

Supporting image 1

Figure 1. Forest plot of the adjusted odds ratios, confidence intervals, and P-value for the association between the comorbidity and the MCID-RAPID3 and CDAI-LDA.


Disclosures: J. Kim, None; K. Shin, None; E. Lee, None; J. Park, None.

To cite this abstract in AMA style:

Kim J, Shin K, Lee E, Park J. Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-comorbidity-on-disease-activity-and-functional-status-in-patients-with-rheumatoid-arthritis-receiving-biologic-dmards-a-longitudinal-analysis-of-the-kobio-ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-comorbidity-on-disease-activity-and-functional-status-in-patients-with-rheumatoid-arthritis-receiving-biologic-dmards-a-longitudinal-analysis-of-the-kobio-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology